Sami Bahçebaşı

Dr. Sami Bahçebaşı

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAli Kirik
Ali Kirik
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Nizameddin KocaNizameddin Koca
Nizameddin Koca
TKTurkan Pasali Kilit
Turkan Pasali Kilit
SSsibel demiral sezer
sibel demiral sezer
TDTeoman Doğru
Teoman Doğru
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
BABanu Açmaz
Banu Açmaz
SBSami Bahçebaşı
Sami Bahçebaşı
EAErdem Aydın
Erdem Aydın
ŞYŞeyma Yıldız
Şeyma Yıldız
İBİfakat İrem Biçer
İfakat İrem Biçer
Introduction: Obesity, particularly morbid obesity, is associated with significant metabolic alterations such as insulin resistance and compensatory hyperinsulinemia. These pathophysiological changes may influence the performance and interpretation of glycemic diagnostic tools, including the oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c). This study is aimed at comparing the diagnostic profiles of OGTT and HbA1c across BMI categories, with a specific focus on morbid obesity and the potential role of elevated insulin levels in test discrepancies. Materials and Methods: This retrospective study included 1031 patients who were classified into nonobese, obese, and morbidly obese groups based on body mass index (BMI). All participants underwent assessment of glycemic status, lipid profile, and related metabolic parameters. Results: Of the study population, 86.8% were female. Based on BMI classification, 56.5% were obese, 35.8% morbidly obese, and 7.8% nonobese. The prevalence of dysglycemia (prediabetes + diabetes) was 43.1% according to HbA1c and 30.9% according to OGTT. Dysglycemia was significantly more frequent in the morbidly obese group by HbA1c ( p < 0.001), while OGTT showed no significant intergroup difference ( p = 0.117). The agreement between methods was low ( κ = 0.326). HbA1c, insulin, HOMA‐IR, CRP, and triglyceride levels increased with BMI. Insulin‐related parameters were higher among HbA1c‐defined dysglycemic individuals. Discussion: HbA1c may be more sensitive in identifying early metabolic disturbances, particularly during the compensatory phase involving hyperinsulinemia. Elevated insulin levels may attenuate glucose response during OGTT, potentially reducing its diagnostic sensitivity.

7 August 2025 in Endocrine
Verified
Journal Article
Closed access
SBSami Bahçebaşı
Sami Bahçebaşı
YŞYasin Şimşek
Yasin Şimşek

30 July 2025 in Journal of the Renin-Angiotensin-Aldosterone System
Verified
Journal Article
Closed access
SBSami Bahçebaşı
Sami Bahçebaşı
ASAhmet Selen
Ahmet Selen
AGAli İhSan Günal
Ali İhSan Günal
Background: Calcium channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors differ in how they affect body fluid balance and kidney function. This study compares the effects of Amlodipine and Ramipril on body fluid compartments in hypertensive patients. Methods: Sixty-four patients with stage 1 hypertension were treated for 8 weeks with either Amlodipine 10 mg (n = 32) or Ramipril 5 mg (n = 32). Body water compartments were assessed using bioimpedance analysis. Blood pressure, kidney function, electrolytes, and spot urine sodium levels were also evaluated. Results: In the Amlodipine group, 23 of 32 patients (72%) showed an increase in total body water, mainly due to interstitial (extracellular) fluid accumulation. Six female patients developed ankle edema. In the Ramipril group, 27 of 32 patients (84%) also had increased total body water, but fluid shifts were more often intracellular or mixed, and no patients developed edema. Ramipril reduced kidney filtration (GFR) and increased potassium levels, while Amlodipine had the opposite effect. No clear link was found between urinary sodium changes and fluid volume shifts in either group. Conclusion: Amlodipine commonly causes extracellular fluid buildup and visible edema, while Ramipril leads to subtle fluid changes and renal effects. Bioimpedance monitoring may help guide individualized treatment.

28 December 2025 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
SBSami Bahçebaşı
Sami Bahçebaşı
BABanu Açmaz
Banu Açmaz
ASAhmet Savranlar
Ahmet Savranlar

21 October 2020 in Drug Metabolism and Personalized Therapy
Verified
Journal Article
Open access
PDF file
UTUlaş Serkan Topaloğlu
Ulaş Serkan Topaloğlu
HTHatice Kayış Topaloğlu
Hatice Kayış Topaloğlu
MKMelih KIZILTEPE
Melih KIZILTEPE
MKMesut Kılıç
Mesut Kılıç
SBSami Bahçebaşı
Sami Bahçebaşı
YŞYasin Şimşek
Yasin Şimşek
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p<0.001). There was also a significant decrease in mean, daily insulin dose, weight and BMI values of patients via IDegAsp. While there was an increase in the amount of dipeptidyl peptidase 4-inhibitors (DPP4-i) and sodium-glucose co-transporter 2-inhibitors (SGLT2-i), there was a decrease in daily injection frequency. There was also a significant decrease in the median values of monthly hypoglycemia rate (from 2.0 to 1.0, p<0.001) and the entire HFS scores (HFS-T: from 1.09 to 0.73, p<0.001; HFS-B: from 0.83 to 0.60, p<0.001; HFS-W: from 1.33 to 0.88, p<0.001). There was a strong positive correlation between ΔHFS-B and daily injection frequency (Rho: 0.398; P: 0.016). Conclusions: IDegAsp co-formulation, combined with DPP4-i and/or SGLT2-i, can provide usefulness in terms of rates of hypoglycemia, reduced HbA1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.